Department of Urology, University of North Carolina, Chapel Hill, NC, United States; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, United States.
Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC, United States.
Cancer Epidemiol. 2022 Jun;78:101913. doi: 10.1016/j.canep.2021.101913. Epub 2021 Mar 3.
Tobacco-use among cancer survivors leads to preventable morbidity, mortality, and increased healthcare costs. We sought to explore the prevalence of smoking and e-cigarette use among survivors of tobacco and non-tobacco related cancers.
A cross-sectional analysis was conducted using the 2015-2018 National Health Interview Survey. Our primary outcome was the prevalence of current cigarette smoking or e-cigarette use among adults with self-reported history of tobacco related or non-tobacco related cancer. Logistic regression analysis was to assess the association of reported cancer type with cigarette smoking or e-cigarette use. Secondary outcomes included yearly trends and dual use.
A total of 12,984 respondents reported a history of cancer, representing a weighted estimate of 5,060,059 individuals with a history of tobacco-related malignancy and 17,583,788 with a history of a tobacco and non-tobacco related cancer, respectively. Survivors of tobacco-related cancers had a significantly higher prevalence of current cigarette use (18.2 % vs 9.7 %, P < 0.0001), e-cigarette use (2.7 % vs 1.6 %, P < 0.0001) and similar rates of dual use. The prevalence of cigarette smoking among all survivors increased as time increased from the year of diagnosis up to 2 years post-diagnosis (P = 0.047). Odds of reporting current cigarette smoking use was higher for survivors of tobacco-related cancers, adjusted for sociodemographic factors (OR1.69, 95 % CI 1.44-1.99).
Survivors of tobacco-related cancers have a higher prevalence of current cigarette smoking and e-cigarette use compared to survivors of non-tobacco related cancers. There was a sequential increase in the prevalence of cigarette use during each subsequent year from the time of a new cancer diagnosis, underscoring the need for long term tobacco cessation support among newly diagnosed adults with cancer.
癌症幸存者吸烟会导致可预防的发病率、死亡率和增加医疗保健成本。我们试图探讨吸烟和电子烟使用在与烟草和非烟草相关癌症幸存者中的流行情况。
使用 2015-2018 年全国健康访谈调查进行横断面分析。我们的主要结局是报告有烟草相关或非烟草相关癌症史的成年人中当前吸烟或电子烟使用的流行率。使用逻辑回归分析评估报告癌症类型与吸烟或电子烟使用的关联。次要结局包括年度趋势和双重使用。
共有 12984 名受访者报告了癌症史,加权估计值为 5060059 人有烟草相关恶性肿瘤史,17583788 人有烟草和非烟草相关癌症史。烟草相关癌症幸存者的当前吸烟率(18.2% vs 9.7%,P<0.0001)、电子烟使用率(2.7% vs 1.6%,P<0.0001)和双重使用率明显更高。随着从诊断年度到诊断后 2 年时间的推移,所有幸存者的吸烟率呈上升趋势(P=0.047)。调整社会人口因素后,烟草相关癌症幸存者报告当前吸烟使用率的几率更高(OR1.69,95%CI 1.44-1.99)。
与非烟草相关癌症幸存者相比,烟草相关癌症幸存者的当前吸烟和电子烟使用率更高。在新发癌症诊断后的每一年,吸烟率呈递增趋势,这突显了需要为新诊断的癌症成年患者提供长期的戒烟支持。